# Governing Trustworthy Agentic Healthcare AI: A Calibration-First Framework with Distributed Ledger Accountability

**Author:** Michael O. Eniolade  
**Affiliation:** University of the Cumberlands  
**Corresponding Author:** Michael O. Eniolade | michael.eniolade@theosyntra.com  
**Paper Type:** Perspective  
**Target Venue:** Blockchain in Healthcare Today (BHTY) — Special Issue: Ethics of AI Agents and Agentic AI in Healthcare  
**Submission Deadline:** June 30, 2026  
**Keywords:** agentic AI, healthcare governance, trustworthy AI, probability calibration, conformal prediction, blockchain, audit trails, distributed ledger technology, clinical decision support, deployment readiness

---

## Abstract

The rapid deployment of agentic artificial intelligence — autonomous, goal-directed systems capable of multi-step reasoning and sequential decision-making — in healthcare settings introduces governance challenges qualitatively different from those addressed by existing clinical AI frameworks. Current standards, including TRIPOD+AI, DECIDE-AI, and the FDA guidance on AI/ML-based software as a medical device, were designed to evaluate static models at deployment and do not address pipeline-level reliability, compounding errors across agent decision steps, or the accountability vacuum created when autonomous systems act at speeds beyond human review. This perspective proposes a five-layer trustworthiness governance framework for agentic healthcare AI that extends model validation standards to encompass: (1) calibration integrity and uncertainty quantification at each agent decision point; (2) subgroup fairness auditing across demographic groups; (3) verifiable model provenance; (4) patient-controlled consent management for autonomous AI actions; and (5) scored deployment readiness with ongoing monitoring criteria. Critically, this paper argues that blockchain and distributed ledger technologies (DLT) are not merely peripheral to this governance agenda — they provide the accountability infrastructure that makes trustworthiness evidence verifiable, persistent, and independently auditable. Immutable audit trails, smart contract-encoded ethical constraints, and decentralized consent registries address the epistemic accountability gap that traditional logging cannot fill. The framework presented here is designed to be operationalizable — each layer carries measurable thresholds — and connects directly to emerging empirical research on clinical AI calibration, conformal prediction, and deployment readiness evaluation.

---

## 1. Introduction

### The Agentic Shift in Healthcare AI

Artificial intelligence in healthcare has crossed a threshold. For more than a decade, clinical AI research focused on a well-defined paradigm: train a model on historical data, validate it against a held-out test set, report discrimination metrics, and evaluate whether predictions exceed a performance threshold. The fundamental unit was a single inference — one patient, one input, one prediction. Clinical decision-support systems operating in this mode function as sophisticated calculators, responding to a clinician's query with a risk score or classification label.

This paradigm is being supplanted by a qualitatively different model of AI deployment. Agentic AI systems — defined here as autonomous, goal-directed software entities capable of multi-step reasoning, tool use, planning, and sequential action — are now being applied across healthcare domains. These systems do not respond to a single prompt and stop. They pursue goals, decompose tasks, invoke external systems, retrieve information, make intermediate decisions, and produce outputs that may themselves trigger further automated actions. Clinical examples include AI systems that autonomously monitor patient deterioration signals across multiple data streams and initiate escalation protocols; diagnostic reasoning agents that iteratively query laboratory and imaging results to refine differential diagnoses; medication safety agents that cross-check orders against patient records, interaction databases, and renal function values; and care coordination systems that schedule, communicate, and adjust clinical workflows without direct human initiation at each step [1,2].

### Why This Changes the Governance Problem

The governance implications of this shift are not incremental — they are structural. When AI acts as a single-inference tool, accountability is straightforward: a clinician requests a prediction, evaluates it, and decides whether to act on it. The AI is a consultant whose opinion can be accepted or rejected. When AI acts as an agent, this structure dissolves. The agent is no longer a consultant — it is a participant in care delivery. Its actions may occur at speeds that preclude human review at each step. Its errors may compound: an incorrect intermediate decision at step two affects all subsequent steps. Responsibility becomes diffuse across the AI system, the developers, the institution, and the clinicians nominally supervising the process.

### The Governance Gap

Existing clinical AI governance frameworks were not designed for this environment. TRIPOD+AI [3] provides reporting standards for model development and validation but addresses models, not pipelines. DECIDE-AI [4] guides the evaluation of clinical decision-support interventions but does not distinguish between single-inference tools and multi-step agents. The FDA's AI/ML-based Software as a Medical Device (SaMD) framework [5] addresses pre-market validation and post-market surveillance but was conceived before agentic deployment became clinically common. The EU AI Act [6] imposes requirements for high-risk AI systems in healthcare but provides limited operational guidance for autonomous pipeline governance. None of these frameworks specifies how to measure, record, or verify trustworthiness at the level of individual agent decisions in a running clinical system.

This paper addresses that gap. We propose a five-layer trustworthiness governance framework specifically designed for agentic healthcare AI, and argue that distributed ledger technologies provide the accountability infrastructure necessary to make this framework operational and verifiable at scale.

---

## 2. What Makes Agentic Healthcare AI Different

Before governance frameworks can be designed, the distinctive properties of agentic AI that create governance challenges must be understood. We identify four properties that differentiate agentic AI from traditional clinical prediction models.

### 2.1 Sequential Decision-Making and Error Compounding

Traditional clinical AI makes a single prediction given a single input. Agentic AI makes sequences of decisions, where each step's output feeds the next step's input. This creates an error compounding dynamic absent from single-inference systems: an overconfident probability estimate at step two, if not flagged and corrected, may propagate into step four as if it were reliable. Calibration — the alignment between predicted probability and true event frequency — matters not only at the final output but at every intermediate decision that affects subsequent steps.

Current calibration evaluation methodology was developed for single-output models. A model's Expected Calibration Error (ECE) is computed over its test set predictions as a whole [7]. In an agentic pipeline, each decision node has its own calibration profile, and aggregate pipeline reliability depends on the product of individual node reliabilities. A pipeline composed of five individually well-calibrated decisions may still produce systematically miscalibrated outputs if calibration error accrues in a consistent direction across nodes [8].

### 2.2 Opacity of Reasoning Chains

Single-inference models can be analyzed using well-established interpretability methods: SHAP values decompose a prediction into feature contributions, calibration curves reveal probability reliability, and permutation importance identifies the features driving a classification. Agentic reasoning chains — particularly those involving large language model (LLM) components, iterative retrieval, or multi-agent orchestration — are substantially harder to audit. The intermediate states between initial input and final recommendation may be partially or fully inaccessible, and their contribution to the final output may not be recoverable after the fact.

This opacity creates an accountability deficit: when an agentic system produces a harmful recommendation, investigators may be unable to identify which reasoning step introduced the error, whether the error reflected a miscalibrated prediction, a biased training distribution, or an inappropriate action at a pipeline junction. Without a durable, auditable record of intermediate states, post-incident analysis becomes speculative.

### 2.3 Speed Beyond Human Review Cycles

A defining property of agentic AI that distinguishes it from traditional decision support is its capacity to act at speeds beyond human review. A triage agent that processes 50 patient deterioration signals per hour cannot be meaningfully supervised by a clinician reviewing each action in real time. Meaningful human oversight, in this context, requires mechanisms beyond real-time review: governance must be embedded in the system's design (pre-deployment constraints, hardcoded boundaries, automatic escalation triggers) and verified through post-hoc audit rather than concurrent human review [9].

### 2.4 Diffuse Moral Responsibility

When a single prediction model is used by a clinician and a patient is harmed, responsibility analysis — however contested — proceeds along a recognizable chain: the model developer, the deploying institution, and the clinician who acted on the recommendation. Agentic pipelines involving multiple AI components, orchestration layers, external data sources, and automated actions dissolve this chain. Responsibility becomes distributed across parties who may each have partial control over some steps and no control over others [10]. This diffusion is not merely a legal problem — it creates practical barriers to learning from failures, holding actors accountable, and deterring unsafe deployment.

---

## 3. The Trustworthiness Gap in Current Governance Frameworks

### 3.1 What Existing Frameworks Address

Several frameworks have emerged to govern clinical AI quality. TRIPOD+AI [3] extends the TRIPOD reporting guideline to include AI-specific transparency requirements: model architecture, training data provenance, calibration reporting, and external validation. DECIDE-AI [4] provides guidance for the evaluation of AI-based clinical decision-support interventions, emphasizing clinical utility alongside statistical performance. The FDA SaMD framework [5] establishes a risk-based regulatory pathway for AI-enabled medical devices, including requirements for pre-market validation and post-market surveillance. The EU AI Act [6] classifies healthcare AI as high-risk and imposes requirements for transparency, documentation, human oversight, and robustness.

### 3.2 What They Miss

Despite their importance, these frameworks share a common limitation: they were designed for model-level evaluation at a point in time, not for ongoing pipeline-level governance of autonomous systems. Specifically:

**Calibration is underspecified.** TRIPOD+AI recommends calibration reporting but provides no threshold standards. Recent systematic reviews have found that calibration is "less commonly assessed" in clinical prediction model evaluations, and that fewer than 13 CKD risk models have ever been externally validated for calibration [11]. The implication for agentic AI governance is that existing frameworks cannot ensure the probability estimates produced by agent decision nodes are reliable enough to support downstream automated actions.

**Uncertainty is absent.** Fewer than 4% of clinical AI studies report any uncertainty measure alongside their predictions [12]. For single-inference tools, this is a quality gap. For agentic systems where uncertain predictions propagate into subsequent automated actions, it is a safety gap. If an agent does not know — and cannot communicate — that its probability estimate at step three carries high uncertainty, it cannot appropriately defer to human review or widen its decision threshold.

**Fairness is aggregate, not pipeline-level.** Where fairness evaluation exists in clinical AI governance, it typically measures whether subgroup performance gaps exist at the level of a model's test set. It does not evaluate whether bias accrues or compounds across agent pipeline steps, or whether demographic disparities in agent recommendations emerge from the interaction of multiple individually unbiased components [13].

**Audit trails are informal and mutable.** No current governance framework specifies what constitutes an adequate audit record for an AI agent's actions. Server logs, model outputs, and database entries are institution-specific, mutable, and not independently verifiable. In a regulatory dispute or adverse event investigation, the absence of immutable, standardized audit records makes accountability analysis unreliable.

**Consent frameworks predate autonomy.** Existing informed consent mechanisms in healthcare AI were designed around patient consent to data use and model deployment — not patient consent to autonomous AI action on their behalf at each step of a clinical process. As agentic AI increasingly acts without direct human mediation, the concept of meaningful consent requires rethinking [14].

---

## 4. A Five-Layer Trustworthiness Governance Framework

We propose a five-layer framework that addresses the gaps identified above. Each layer carries measurable criteria and is designed to be applied both pre-deployment and as a continuous monitoring protocol for running agentic systems.

### Layer 1: Reliability Evaluation

Reliability evaluation governs whether the probability outputs produced by each agent decision node are trustworthy enough to support downstream automated action.

**Calibration assessment** requires computing the Expected Calibration Error (ECE) for each decision node using empirical frequency analysis across probability bins [7]. An ECE ≤ 0.10 is proposed as a minimum deployment threshold, consistent with emerging clinical AI quality standards. The Brier Score and Brier Skill Score [15] provide complementary summary measures. Critically, calibration must be evaluated not only on the original training distribution but on the distribution of inputs the deployed agent actually encounters — including the heterogeneous, missing-data-rich inputs characteristic of real clinical environments.

**Uncertainty quantification** using split conformal prediction [8] provides distribution-free coverage guarantees at each decision node. Rather than a single probability estimate, conformal prediction produces a prediction set — a set of possible outputs guaranteed to contain the true label with probability 1−α, where α is the chosen miscoverage rate. For clinical agentic AI, a coverage guarantee of ≥ 0.90 is proposed, ensuring that the agent communicates not just its best prediction but the range of outcomes it cannot rule out. When prediction sets include multiple labels (ambiguous predictions), the agent should be designed to defer to human review rather than proceed autonomously.

**External validation** is required before deployment: calibration metrics should be recomputed on a prospectively collected or geographically distinct external dataset to measure calibration drift — the degradation of probability reliability when the model encounters a new clinical environment [11].

### Layer 2: Fairness Auditing

Fairness auditing governs whether agent reliability is equitably distributed across patient subgroups.

Calibration should be stratified by age group (e.g., < 65 vs. ≥ 65), sex, race/ethnicity where available, and clinically relevant comorbidity groups (e.g., diabetes status, chronic kidney disease stage). A maximum allowable ECE gap of 0.05 between any two demographic subgroups is proposed as a deployment gate. Where subgroup calibration gaps exceed this threshold, targeted recalibration on underrepresented groups or deployment restriction to populations where calibration is demonstrated should be required.

False negative disparity — the difference in false negative rates across subgroups — deserves particular attention in healthcare AI, where missed diagnoses disproportionately harm already-disadvantaged groups [13]. An agent that is well-calibrated overall but systematically underestimates risk for elderly patients or patients from racial minority groups amplifies existing healthcare inequities rather than reducing them.

### Layer 3: Provenance Verification

Provenance verification governs whether the lineage of an agent's models and training data can be independently verified.

**Model versioning** requires each deployed agent decision node to carry a verifiable identifier — a cryptographic hash of the model weights and architecture — recorded at deployment. Any change to the model, including recalibration, fine-tuning, or architecture modification, must generate a new identifier and a new deployment record.

**Training data documentation** requires that the characteristics of training datasets — size, demographic composition, data source, collection period, and preprocessing steps — be documented and verifiable. This documentation must be sufficient to allow an independent reviewer to assess whether the training distribution is representative of the deployment environment.

**Deployment history** records when each model version was deployed, to which clinical contexts, and under what oversight conditions. This record enables post-incident analysis: when a patient is harmed, investigators can identify exactly which model version was running at the time, what it was trained on, and whether its deployment conditions matched its validation conditions.

### Layer 4: Consent Management

Consent management governs the scope of autonomous AI action to which a patient has agreed.

Current consent frameworks in healthcare AI address consent to data use and model deployment at the institutional level. Agentic AI requires consent to be more granular: a patient should be able to specify whether they consent to autonomous AI actions affecting their care plan, whether they require human review before AI-initiated actions take effect, and whether they can override an AI agent's recommendation at any step.

This requires a consent architecture capable of expressing, storing, and enforcing these preferences — and of updating them as the patient's care context changes. Static institutional consent forms signed at admission are insufficient for an environment where AI agents may act on a patient's behalf across multiple care episodes, data systems, and clinical teams.

### Layer 5: Deployment Readiness and Ongoing Monitoring

Deployment readiness scoring integrates the preceding four layers into a structured pre-deployment gate and a continuous post-deployment monitoring protocol.

Pre-deployment, each agent is assessed against a deployment readiness checklist encompassing: (1) discrimination adequacy (AUROC ≥ 0.85 on external validation); (2) calibration adequacy (ECE ≤ 0.10 on external validation); (3) calibration stability (calibration drift ≤ 0.05 across internal and external datasets); (4) uncertainty coverage (conformal coverage ≥ 0.90 on external validation); (5) coverage stability (coverage drift ≤ 0.05 across datasets); (6) prediction interpretability (singleton rate ≥ 0.70 — proportion of instances receiving an unambiguous prediction); (7) subgroup calibration equity (ECE gap across subgroups ≤ 0.05); and (8) transparency and reproducibility (full code, data pipeline, and model documentation publicly or institutionally accessible) [16].

Post-deployment, ongoing monitoring tracks calibration drift over time using sequential ECE monitoring with statistical process control alerts. A statistically significant increase in ECE above the deployment threshold triggers a mandatory review cycle and, if not resolved, mandatory decommissioning.

---

## 5. Distributed Ledger Technologies as Accountability Infrastructure

### 5.1 Why Traditional Logging Is Insufficient

The trustworthiness framework described above generates a substantial body of evidence: calibration metrics, fairness audits, provenance records, consent documents, deployment readiness scores, and ongoing monitoring data. For this evidence to support accountability — in regulatory review, adverse event investigation, or litigation — it must be durable, verifiable, and independent of any single institution's control.

Traditional server logs and database records fail on all three criteria. They are mutable: records can be altered by administrators with access. They are siloed: records from different components of a multi-institutional agentic pipeline may be stored in incompatible systems without a common reference. They are not independently verifiable: an institution claiming that its AI agent behaved correctly at a given time cannot provide proof that its own internal records have not been modified.

These limitations are not merely theoretical. In healthcare environments where AI agents may act across institutional boundaries — a diagnostic agent querying a regional radiology system, a triage agent integrating data from multiple hospitals — no single institution's logging architecture can provide an authoritative audit record of the full pipeline.

### 5.2 Blockchain-Based Audit Trails

Blockchain and distributed ledger technologies address these limitations through properties that are architecturally suited to the accountability requirements of agentic healthcare AI.

**Immutability** means that once a transaction is written to the ledger, it cannot be altered without consensus from the network — making post-hoc modification of audit records computationally and organizationally prohibitive. For agentic AI governance, each significant agent decision — a risk score above a clinical threshold, an automated order, a care plan modification — can be written as an on-chain transaction, creating a tamper-resistant record of what the agent did, when, on what inputs, and with what output.

**Verifiability** means that any authorized party can independently confirm that a record has not been modified since it was written. A regulatory auditor, a patient's legal representative, or a clinical ethics committee can verify the audit trail of an AI agent's actions without depending on the deploying institution's attestation.

**Decentralization** means that the audit record is not controlled by any single party. In a multi-institutional agentic pipeline, a shared distributed ledger allows each participant to contribute to and verify the record without any single party having unilateral control over what the record says [17].

**Smart contracts** enable the encoding of governance rules as executable code running on the ledger. Rather than relying on institutional policy to enforce that an agent defers to human review when uncertainty exceeds a threshold, a smart contract can enforce this rule automatically: if an agent's conformal prediction set contains multiple labels, the smart contract blocks autonomous action and generates a human escalation event recorded on-chain. This transforms governance rules from aspirational policies into operational constraints [18].

### 5.3 Decentralized Consent Management

Patient consent for autonomous AI action is particularly well-suited to blockchain-based management. A consent record written to a distributed ledger is patient-controlled, institution-independent, and auditable. A patient who consents to AI-assisted triage but not AI-initiated medication changes can express this granular preference in a consent record that any component of the agentic pipeline can query before taking an action.

Smart contracts can enforce consent boundaries in real time: when an AI agent proposes an action, the contract checks whether that action class falls within the patient's recorded consent scope and blocks it if not — generating a logged exception for human review. This architecture gives consent teeth: it is not simply a document signed at admission but a live constraint on system behavior.

### 5.4 Verifiable Model Provenance

The provenance requirements described in Layer 3 of the governance framework are directly implementable using on-chain model registries. When a new model version is deployed, its cryptographic hash — computed from the model weights, architecture specification, and training data characteristics — is written to the ledger. Any subsequent query to the agent can verify, in real time, that the model responding to the query is the registered, validated version and not a modified derivative.

This is particularly important in environments where models are periodically updated: a post-deployment recalibration that improves performance on a new patient population may inadvertently degrade performance on a previously studied subgroup. An on-chain model registry makes every version change traceable, reversible, and independently verifiable [19].

### 5.5 Federated Learning for Privacy-Preserving Distributed Governance

Governance at scale — across multiple hospitals, health systems, and jurisdictions — requires access to diverse patient populations for calibration validation and fairness auditing. Federated learning enables models to be trained and calibrated across distributed datasets without centralizing sensitive patient data, with distributed ledger technologies providing the coordination, verification, and audit infrastructure for the federated process [20].

Each participating institution trains on its local data, contributes gradient updates or model statistics to the federated process, and receives in return a globally calibrated model whose performance has been verified across the federation's full population diversity. The ledger records each institution's participation, the aggregation protocol used, and the resulting model provenance — providing accountability for the full federated governance process.

---

## 6. Implementation Challenges

The framework proposed here is architecturally sound, but its implementation faces challenges that a research agenda must address honestly.

### 6.1 Latency and Throughput

Writing audit transactions to a distributed ledger introduces latency that may be incompatible with real-time clinical decision support. A triage agent that must write an on-chain transaction for each decision step faces throughput constraints that could delay time-sensitive interventions. Architectural solutions including off-chain computation with on-chain commitment, periodic batch anchoring of audit summaries, and layer-2 scaling protocols can mitigate this, but they require careful design to preserve the immutability properties that motivate on-chain governance in the first place.

### 6.2 Interoperability with Existing Health Information Systems

Healthcare institutions operate across a heterogeneous landscape of electronic health record systems, laboratory information systems, and clinical data warehouses that predate blockchain-based architectures. Integrating on-chain governance with existing health information infrastructure requires FHIR-compliant data exchange, HL7 interface standards, and institutional commitment to adopting new auditing protocols. The governance framework cannot be imposed on existing systems without substantial integration engineering.

### 6.3 GDPR and the Right to Erasure

Blockchain's immutability creates a direct tension with GDPR's right to erasure [21]. A patient who invokes the right to have their data deleted cannot have that data removed from an immutable ledger. Architectural solutions — including storing only cryptographic commitments on-chain and personal data off-chain, with erasure implemented by deleting the off-chain data and rendering the commitment unresolvable — preserve both immutability of the audit record and the practical effect of erasure. However, the legal adequacy of this approach requires regulatory clarification in healthcare contexts.

### 6.4 Institutional Adoption and Governance

Distributed ledger governance requires consortium formation among participating institutions — agreement on ledger architecture, consensus mechanisms, access control, and governance of the governance layer itself. Healthcare institutions accustomed to managing their own data infrastructure may resist participation in a shared ledger they do not unilaterally control. Building the institutional trust and regulatory legitimacy for cross-institutional blockchain-based AI governance is a sociotechnical challenge that technical architecture alone cannot solve.

### 6.5 Clinician Trust Calibration

The governance framework described here is designed primarily around system-level accountability. But agentic AI governance also has a human dimension: clinicians must be neither over-reliant on AI agent recommendations nor systematically distrustful of them. Calibration, in this context, refers not only to probability reliability but to the alignment between a clinician's confidence in an AI recommendation and the AI's actual reliability. Governance frameworks that improve system trustworthiness must also invest in clinician education about when and how to appropriately weight AI recommendations.

---

## 7. Research Agenda

The framework proposed here is a conceptual contribution that requires empirical validation. We identify five research priorities.

**Priority 1: Empirical calibration evaluation of deployed clinical AI.** The framework's reliability layer requires that calibration be measured and documented for each agent decision node. Large-scale empirical studies measuring ECE, Brier scores, and conformal coverage rates across deployed clinical AI systems — including agentic pipelines — would establish the current state of the field and identify where governance intervention is most urgently needed.

**Priority 2: Smart contract frameworks for clinical AI ethical constraints.** The formal specification of governance rules in smart contract code — particularly escalation triggers, consent enforcement, and calibration drift alerts — requires the development of healthcare-specific smart contract templates validated against clinical governance requirements. Piloting these frameworks in simulated clinical environments would provide evidence of operational feasibility.

**Priority 3: Cross-institutional federated governance pilots.** The federated learning and distributed governance architecture described in Section 5.5 requires multi-institutional pilots to evaluate feasibility, latency, interoperability, and governance dynamics. Such pilots would also generate the diverse external validation datasets needed to properly evaluate calibration stability and subgroup fairness across institutional settings.

**Priority 4: Patient-facing uncertainty communication standards.** If conformal prediction is to be used to communicate uncertainty to patients and clinicians in a way that supports informed consent and meaningful oversight, standards are needed for how uncertainty should be displayed, interpreted, and acted upon in clinical interfaces. Human factors research on uncertainty communication in clinical decision support is needed to bridge the technical and human dimensions of the governance framework.

**Priority 5: Prospective evaluation of DLT audit trails in adverse event investigation.** The value of blockchain-based audit trails can ultimately only be demonstrated by studying their use in actual adverse event investigations. Prospective studies comparing the completeness, accuracy, and usefulness of on-chain vs. conventional audit records in clinical AI incident reviews would provide the evidence base needed to justify the significant investment required for DLT adoption in healthcare AI governance.

---

## 8. Conclusion

Agentic AI in healthcare is not a future prospect — it is a present reality. Systems that autonomously monitor, reason, and act on behalf of patients are already in clinical use, and their capabilities are expanding rapidly. The governance frameworks currently available to healthcare institutions, regulators, and patients were designed for a simpler world: a model produces a prediction, a clinician evaluates it, a patient receives care. In a world where AI agents make sequential decisions at machine speed, those frameworks leave critical accountability gaps unfilled.

The five-layer trustworthiness governance framework proposed here — integrating reliability evaluation, fairness auditing, provenance verification, consent management, and deployment readiness scoring — addresses those gaps with measurable, operationalizable criteria. Distributed ledger technologies provide the accountability infrastructure that makes this framework verifiable: immutable audit trails, smart contract-enforced constraints, decentralized consent registries, and on-chain model provenance records transform governance from aspirational policy into operational architecture.

Trustworthiness in agentic healthcare AI cannot be certified once at deployment and assumed thereafter. It must be earned continuously, measured rigorously, and verified independently. The framework presented here offers one path toward that goal — and a research agenda for the work required to validate it.

---

## Acknowledgments

The author acknowledges the growing body of clinical AI governance scholarship that informed this perspective, particularly the TRIPOD+AI, DECIDE-AI, and emerging conformal prediction frameworks for clinical uncertainty quantification.

---

## Conflicts of Interest

The author declares no conflicts of interest relevant to the content of this manuscript.

---

## References

*(Vancouver numbered style — to be finalized with full citations before submission)*

1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
2. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31-8.
3. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.
4. Vasey B, Nagendran M, Campbell B, et al. Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. BMJ. 2022;377:e070904.
5. U.S. Food and Drug Administration. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. 2021.
6. European Parliament. Regulation (EU) 2024/1689 of the European Parliament and of the Council — Artificial Intelligence Act. 2024.
7. Guo C, Pleiss G, Sun Y, Weinberger KQ. On calibration of modern neural networks. Proceedings of the 34th International Conference on Machine Learning. 2017;70:1321-30.
8. Angelopoulos AN, Bates S. A gentle introduction to conformal prediction and distribution-free uncertainty quantification. Found Trends Mach Learn. 2023;16(4):494-591.
9. Choudhury A, Asan O. Role of artificial intelligence in patient safety outcomes: systematic literature review. JMIR Med Inform. 2020;8(7):e18599.
10. Morley J, Cowls J, Taddeo M, Floridi L. Ethical guidelines for AI in public service. Government Information Quarterly. 2021;38(3):101577.
11. Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney disease and its progression: a systematic review. PLoS Med. 2012;9(11):e1001344.
12. Campagner A, Ciucci D, Cabitza F. Modeling the unknown: on the role of uncertainty in machine learning for healthcare — a scoping review. Comput Methods Programs Biomed. 2025;[in press].
13. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-53.
14. Mittelstadt B, Allo P, Taddeo M, Wachter S, Floridi L. The ethics of algorithms: mapping the debate. Big Data Soc. 2016;3(2):2053951716679679.
15. Brier GW. Verification of forecasts expressed in terms of probability. Mon Weather Rev. 1950;78(1):1-3.
16. Collins GS, Dhiman P, Ma J, et al. Evaluation of clinical prediction models (part 1): from development to external validation. BMJ. 2024;384:e074819.
17. Ekblaw A, Azaria A, Halamka JD, Lippman A. A case study for blockchain in healthcare: "MedRec" prototype for electronic health records and medical research data. Proceedings of IEEE Open & Big Data Conference. 2016.
18. Macrinici D, Cartofeanu C, Gao S. Smart contract applications within blockchain technology: a systematic mapping study. Telemat Inform. 2018;35(8):2337-54.
19. Kuo TT, Kim HE, Ohno-Machado L. Blockchain distributed ledger technologies for biomedical and health care applications. J Am Med Inform Assoc. 2017;24(6):1211-20.
20. Rieke N, Hancox J, Li W, et al. The future of digital health with federated learning. npj Digit Med. 2020;3(1):119.
21. Finck M. Blockchains and the General Data Protection Regulation. European Parliamentary Research Service. 2017.

---

*Draft version 1.0 — April 2026. All sections complete; references require DOI verification before submission.*
